Proton pump inhibitor treatment for acute peptic ulcer bleeding

Prevention of post‐sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial

“…This is the first prospective randomized study to determine the potential role of PPI in reducing the risk of post‐EST bleeding. In spite of the promising effects of PPIs in preventing rebleeding from peptic ulcers, we found that the use of PPI failed to reduce both immediate and delayed bleeding after EST. There were also no differences in other important clinical outcomes, including a need for blood transfusion, the length of hospital stay and 30‐day mortality.…”

“…PPIs have been shown to reduce significantly the risk of rebleeding from peptic ulcer disease after the initial endoscopic hemostasis, presumably by raising the intragastric pH and thereby enhancing platelet aggregation and clot stabilization. Pre‐emptive PPI have also been shown to reduce the need for endoscopic therapy when given to patients presenting with upper gastrointestinal bleeding .…”

Prevention of post‐sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial

“…This is the first prospective randomized study to determine the potential role of PPI in reducing the risk of post‐EST bleeding. In spite of the promising effects of PPIs in preventing rebleeding from peptic ulcers, we found that the use of PPI failed to reduce both immediate and delayed bleeding after EST. There were also no differences in other important clinical outcomes, including a need for blood transfusion, the length of hospital stay and 30‐day mortality.…”

“…PPIs have been shown to reduce significantly the risk of rebleeding from peptic ulcer disease after the initial endoscopic hemostasis, presumably by raising the intragastric pH and thereby enhancing platelet aggregation and clot stabilization. Pre‐emptive PPI have also been shown to reduce the need for endoscopic therapy when given to patients presenting with upper gastrointestinal bleeding .…”

Gastric acid inhibition in the treatment of peptic ulcer hemorrhage

“…In a randomized, controlled study, they treated patients with intravenous high-dose omeprazole (80-mg bolus and 8 mg/h for 72 h) or placebo and documented signifi cant decreases in the ulcer rebleeding rate, need for transfusion, and length of hospital stay. These fi ndings have been confi rmed in other clinical trials and in meta-analyses of the use of PPIs in peptic ulcer bleeding [20][21][22].…”

Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding

“…The rebleeding rate of 16 per cent in the standard‐dose group was not particularly high and was lower than the rebleeding rate (22 per cent) in the placebo arm of the Lau study7. It is more comparable to the 13·2 per cent probability of rebleeding reported in a pooled analysis of data from eight trials of high‐dose PPI infusion15. The rebleeding rate for the high‐dose group in the present study (3 per cent) is comparable to that of 6·7 per cent reported in the Lau study7.…”

Prevention of post‐sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial

“…This is the first prospective randomized study to determine the potential role of PPI in reducing the risk of post‐EST bleeding. In spite of the promising effects of PPIs in preventing rebleeding from peptic ulcers, we found that the use of PPI failed to reduce both immediate and delayed bleeding after EST. There were also no differences in other important clinical outcomes, including a need for blood transfusion, the length of hospital stay and 30‐day mortality.…”

“…PPIs have been shown to reduce significantly the risk of rebleeding from peptic ulcer disease after the initial endoscopic hemostasis, presumably by raising the intragastric pH and thereby enhancing platelet aggregation and clot stabilization. Pre‐emptive PPI have also been shown to reduce the need for endoscopic therapy when given to patients presenting with upper gastrointestinal bleeding .…”

Gastric acid inhibition in the treatment of peptic ulcer hemorrhage

“…In a randomized, controlled study, they treated patients with intravenous high-dose omeprazole (80-mg bolus and 8 mg/h for 72 h) or placebo and documented signifi cant decreases in the ulcer rebleeding rate, need for transfusion, and length of hospital stay. These fi ndings have been confi rmed in other clinical trials and in meta-analyses of the use of PPIs in peptic ulcer bleeding [20][21][22].…”

Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding

“…The rebleeding rate of 16 per cent in the standard‐dose group was not particularly high and was lower than the rebleeding rate (22 per cent) in the placebo arm of the Lau study7. It is more comparable to the 13·2 per cent probability of rebleeding reported in a pooled analysis of data from eight trials of high‐dose PPI infusion15. The rebleeding rate for the high‐dose group in the present study (3 per cent) is comparable to that of 6·7 per cent reported in the Lau study7.…”

Prevention of post‐sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial

“…This is the first prospective randomized study to determine the potential role of PPI in reducing the risk of post‐EST bleeding. In spite of the promising effects of PPIs in preventing rebleeding from peptic ulcers, we found that the use of PPI failed to reduce both immediate and delayed bleeding after EST. There were also no differences in other important clinical outcomes, including a need for blood transfusion, the length of hospital stay and 30‐day mortality.…”

“…PPIs have been shown to reduce significantly the risk of rebleeding from peptic ulcer disease after the initial endoscopic hemostasis, presumably by raising the intragastric pH and thereby enhancing platelet aggregation and clot stabilization. Pre‐emptive PPI have also been shown to reduce the need for endoscopic therapy when given to patients presenting with upper gastrointestinal bleeding .…”

Gastric acid inhibition in the treatment of peptic ulcer hemorrhage

“…In a randomized, controlled study, they treated patients with intravenous high-dose omeprazole (80-mg bolus and 8 mg/h for 72 h) or placebo and documented signifi cant decreases in the ulcer rebleeding rate, need for transfusion, and length of hospital stay. These fi ndings have been confi rmed in other clinical trials and in meta-analyses of the use of PPIs in peptic ulcer bleeding [20][21][22].…”

Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding

“…The rebleeding rate of 16 per cent in the standard‐dose group was not particularly high and was lower than the rebleeding rate (22 per cent) in the placebo arm of the Lau study7. It is more comparable to the 13·2 per cent probability of rebleeding reported in a pooled analysis of data from eight trials of high‐dose PPI infusion15. The rebleeding rate for the high‐dose group in the present study (3 per cent) is comparable to that of 6·7 per cent reported in the Lau study7.…”